Top Page
PainReform
(NASDAQ:PRFX)
PainReform (PRFX) vs. SPDR S&P 500 ETF (SPY)
PainReform Business Overview & Revenue Model
PainReform Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 86.00K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -16.00K | -15.00K | 71.00K | ― | 0.00 |
| EBITDA | -3.94M | -14.55M | -9.57M | -8.76M | -7.20M | -1.67M |
| Net Income | -4.09M | -14.59M | -9.34M | -8.79M | -7.25M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 11.16M | 4.53M | 9.93M | 12.33M | 19.07M | 17.80M |
| Cash, Cash Equivalents and Short-Term Investments | 3.48M | 4.26M | 8.03M | 4.10M | 16.54M | 15.68M |
| Total Debt | 56.00K | 45.00K | 86.00K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.72M | 2.70M | 2.69M | 1.31M | 991.00K | 1.18M |
| Stockholders Equity | 8.44M | 1.82M | 7.24M | 11.02M | 18.08M | 16.62M |
Cash Flow | ||||||
| Free Cash Flow | -5.96M | -12.63M | -6.69M | -6.46M | -6.60M | -2.57M |
| Operating Cash Flow | -5.96M | -12.62M | -6.68M | -6.46M | -6.55M | -2.56M |
| Investing Cash Flow | -51.00K | -13.00K | 5.99M | -6.01M | -50.00K | -10.00K |
| Financing Cash Flow | 6.70M | 8.86M | 4.62M | 0.00 | 7.48M | 17.31M |
PainReform Technical Analysis
PainReform Risk Analysis
PainReform Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $6.67M | ― | ― | ― | ― | ― | |
44 Neutral | $2.99M | ― | ― | ― | ― | ― | |
42 Neutral | $6.43M | -1.24 | -42.47% | ― | -26.92% | 69.90% | |
40 Underperform | $18.95M | -0.71 | -63.82% | ― | ― | ― | |
32 Underperform | $3.56M | -0.10 | -9999.00% | ― | ― | 79.31% |
PainReform Corporate Events
On January 20, 2026, PRF Technologies announced it had filed its first patent application for proprietary micro-climate modeling methods designed to significantly enhance the accuracy of power production forecasts at individual solar plants. The filing, which follows the company’s acceptance into the NVIDIA Connect Program, underpins its DeepSolar Predict forecasting platform and targets a key weakness in conventional, region-based solar forecasts by continuously adapting to localized weather conditions at each installation. By improving short-term and intraday forecast precision, PRF aims to help utility-scale solar operators and energy traders better manage revenue, reduce penalties tied to forecast errors, and optimize participation in volatile electricity markets. The move strengthens PRF’s growing portfolio of energy-focused intellectual property and supports its broader strategy to expand in data-driven renewable energy optimization, potentially reinforcing its position at the intersection of AI, clean energy, and financial performance for solar assets.
The most recent analyst rating on (PRFX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On January 15, 2026, PainReform Ltd. announced it had changed its corporate name to PRF Technologies Ltd., following shareholder approval at the company’s January 6, 2026 annual general meeting, in a move designed to signal its evolution beyond a single-asset pain-treatment developer into a diversified healthcare and clean-energy technology platform. The rebranding highlights the company’s broadened portfolio, which now includes LayerBio’s OcuRing-K sustained-release ocular therapy for post-cataract surgery care and the DeepSolar AI-based solar analytics and forecasting business, positioning PRF to pursue multiple growth paths and reduce reliance on any single product as it targets large, high-growth markets in both specialty pharmaceuticals and renewable energy.
The most recent analyst rating on (PRFX) stock is a Sell with a $0.78 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On January 12, 2026, PainReform and its majority-owned subsidiary LayerBio reported that their OcuRing™-K drop-less, sustained-release intraocular drug delivery platform for cataract surgery demonstrated a favorable safety profile in a series of preclinical rabbit studies and a Phase I human clinical trial. The studies found no treatment-related adverse events, no serious adverse events, proper positioning of the investigational product and intraocular lenses in all treated eyes, and no meaningful safety differences versus controls, reinforcing the platform’s tolerability and biocompatibility and supporting advancement toward investigational new drug-enabling activities and later-stage clinical development in the United States, a step that could strengthen PainReform’s positioning in ophthalmic drug delivery and post-surgical care.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On January 7, 2026, PainReform Ltd. filed a Form 6-K in the United States providing updated financial disclosure related to its acquisition of LayerBio Inc., a transaction first announced in July 2025 and completed on August 13, 2025, in which PainReform acquired 7,331,378 preferred shares representing a 51% controlling stake. The filing supplies investors with unaudited pro forma condensed combined financial information as if the deal had occurred on January 1, 2024 and June 30, 2025, along with LayerBio’s audited financial statements for 2023 and 2024 and unaudited financials for the six months ended June 30, 2025, clarifying that the acquisition qualifies as a business combination but is less than 50% significant under SEC tests and that the pro forma figures are illustrative only, without assumed synergies or forward projections, to better inform stakeholders about the combined company’s historical financial profile.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On January 6, 2026, PainReform Ltd. held its Adjourned Annual General Meeting of Shareholders, at which investors approved all six proposals presented, each receiving the required majority vote. The approvals, following an earlier notice and proxy process initiated in November 2025, clear the way for the company to implement its planned corporate and governance actions as set out to shareholders, reinforcing management’s mandate and shaping the company’s operational and strategic direction for the coming year.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On January 5, 2026, PainReform announced that its DeepSolar business unit launched Smart TDD, a next-generation solar technical due diligence service designed to deliver faster, more accurate, and more comprehensive audits of solar asset performance and risk across the $60 billion-plus global solar asset M&A market. By offering full data coverage of components and operational history, AI- and physics-based diagnostics, clearly prioritized findings, and rapid turnaround times, Smart TDD aims to replace traditional sampling- and manual inspection-based approaches, supporting investors, independent power producers, infrastructure funds, operators, lenders, and insurers at key lifecycle points such as commissioning, underperformance diagnosis, warranty expiry, and asset transactions; the launch reinforces DeepSolar’s positioning as a trusted analytics partner in a rapidly growing and increasingly complex solar secondary market, where aging assets and accelerating deal activity are driving heightened demand for high-quality, scalable technical diligence services.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On December 30, 2025, PainReform Ltd. convened its Annual General Meeting of Shareholders in Tel Aviv but was unable to proceed with the meeting’s agenda due to a lack of quorum. As a result, the company adjourned the meeting for one week and scheduled it to be reconvened on January 6, 2026, at the same time and location at its legal counsel’s offices in Tel Aviv, signaling a minor procedural delay in its routine corporate governance process but no announced changes to operations or strategy.
The most recent analyst rating on (PRFX) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
On December 10, 2025, PainReform Ltd. announced the successful R&D assessment of its LayerBio drop-less, sustained-release ocular platform, confirming its ability to incorporate multiple drug entities. This development supports the platform’s potential to improve pharmacological efficiency and simplify postoperative care for cataract patients by reducing the need for medicated eye drops. The platform’s ability to incorporate corticosteroids and NSAIDs highlights its technical feasibility for multi-drug use, offering significant advantages in patient comfort and compliance, especially for elderly cataract patients.
On December 2, 2025, PainReform Ltd. announced the commencement of its development plan for OcuRing™-K, a sustained-release ocular therapy designed for post-cataract surgery pain and inflammation management. This initiative marks a significant step in addressing the limitations of traditional eye-drop regimens by offering a drop-less, intraoperatively administered solution. The development plan follows PainReform’s majority investment in LayerBio and aims to advance OcuRing-K into Phase II clinical trials, potentially impacting the multi-billion-dollar global cataract surgery market by improving treatment consistency and patient compliance.
On November 25, 2025, PainReform Ltd. announced its upcoming Annual General Meeting of Shareholders scheduled for December 30, 2025, in Tel Aviv, Israel. The meeting’s agenda includes significant proposals such as the re-election of Dr. Ehud Geller to the Board, a name change to PRF Ltd., an increase in authorized share capital, a reverse stock split, and the re-appointment of Kesselman & Kesselman as the company’s auditors. These proposals, if approved, could impact the company’s operational structure and market identity, potentially influencing shareholder value and market perception.
On November 12, 2025, PainReform Ltd. announced that its solar energy unit, DeepSolar, has made significant progress in developing an AI-driven automated reporting engine for solar-asset analysis. This new engine is designed to streamline the process of producing performance reports, which are crucial for assessing operational and financial performance of solar plants. By automating data consolidation and analysis, the engine aims to deliver customized, insight-rich reports quickly, enhancing decision-making and maximizing asset performance. This advancement is expected to strengthen PainReform’s position in the renewable energy sector by making AI capabilities more practical and accessible, ultimately translating operational data into clear financial insights and business value.
On November 5, 2025, PainReform Ltd. announced that its solar energy unit, DeepSolar, was featured in a Watchlist Interview by The Market Link, highlighting its participation in the NVIDIA Connect program. The interview emphasized DeepSolar’s development of ‘DeepSolar Predict,’ an AI-based forecasting module designed to enhance energy production forecasts and operational decisions for solar-asset managers. This advancement addresses the growing complexity in utility-scale solar operations by improving forecast accuracy and profitability. DeepSolar is making progress toward its first pilot projects, signaling potential long-term value creation for investors and partners.